BridgeBio Pharma (BBIO) AI Stock Analysis

• Market Cap: $12.83B
• Dividend Yield: N/A
• Average Volume (3M): 3.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: 62.46%
• EPS Growth: -73.59%
• Country: US
• Employees: 725
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.00
• Shares Outstanding: 193,862,870
• 10 Day Avg. Volume: 3,070,739
• 30 Day Avg. Volume: 3,047,866
• PEG Ratio: -0.65
• Price to Book (P/B): -7.27
• Price to Sales (P/S): 30.05
• P/FCF Ratio: -33.75
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 29.54
• Enterprise Value/Gross Profit: 31.30
• Enterprise Value/Ebitda: -23.82
• 1Y Price Target: $103.00
• Price Target Upside: 57.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 17
• EPS Forecast (FY): -1.67
• Revenue Forecast (FY): $924.05M

• Rating: 50 Neutral
• Price Target: $68.00 ▲(4.04% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is held down primarily by weak financials (large losses, heavy cash burn, and negative equity) and bearish technical momentum. These are partially offset by a constructive earnings-call outlook driven by strong Atruby growth and multiple positive late-stage pipeline readouts, while valuation support is limited given ongoing losses and no dividend.

Positive Factors

Revenue acceleration & high gross margins

Rapid revenue acceleration combined with exceptionally high gross margins indicates Atruby (and future products) have scalable unit economics. With margins near 98–99%, incremental sales are highly profitable, enabling operating leverage as SG&A growth stabilizes and supporting durable margin expansion as commercialization matures.

Established commercial traction for Atruby

Strong prescription growth, rapid quarter-over-quarter revenue gains, and growing prescriber breadth point to durable market adoption in ATTR-CM. This recurring commercial base improves predictability of cash flows and provides a proven launch playbook the company can replicate for additional indications and new product rollouts.

Multiple positive late‑stage readouts de‑risk pipeline

Multiple successful Phase 3 results materially reduce clinical and regulatory risk versus a single success path. This raises the probability of near-term approvals, accelerates potential revenue diversification beyond Atruby, and strengthens long-term growth optionality by turning R&D programs into more predictable commercial assets.

Negative Factors

Negative shareholders’ equity

A large accumulated deficit and materially negative equity limit the company’s financial cushion to absorb continued operating losses or unforeseen costs. Even after debt reduction, negative equity heightens refinancing and covenant risk, increasing the likelihood of dilutive financing or restrictive capital terms if cash burn persists.

Sustained high cash burn and negative free cash flow

Large, persistent cash outflows (~$446M in 2025) reflect ongoing R&D and commercialization investment and imply continued dependence on external financing or asset monetization. Even with runway improvements, heavy cash burn remains a structural risk to capital sufficiency and shareholder dilution over the next 2–3 years if revenue growth or margin gains lag expectations.

Revenue concentration & IP/legal uncertainty

A large share of revenue currently comes from one product (Atruby), leaving the company exposed to competitor entry, pricing or uptake shocks. Concurrent tafamidis IP uncertainty and related litigation create a structural downside risk to market exclusivity and adoption, which could materially affect near‑term cash flow and strategic positioning.

BridgeBio Pharma Business Overview & Revenue Model

Company Description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

How the Company Makes Money

BridgeBio Pharma generates revenue through a combination of product sales, partnerships, and collaborations. The company typically monetizes its drug candidates by advancing them through clinical trials and seeking regulatory approvals, after which they can be commercially launched. Key revenue streams include milestone payments from collaborations with larger pharmaceutical companies, royalties on product sales, and potential licensing agreements. Additionally, significant partnerships with industry leaders can provide upfront payments and shared research funding, contributing to the company’s financial stability and growth.

BridgeBio Pharma Financial Statement Overview

Summary

Strong revenue acceleration and exceptionally high gross margins are positives, but the company remains deeply unprofitable with heavy ongoing cash burn. Despite a major reduction in reported debt in 2025, persistently negative equity and large operating losses keep financial risk elevated.

Income Statement

Revenue accelerated sharply, rising from $221.9M (2024) to $362.4M (2025), after a low base in 2023—showing improving commercial traction. Gross margin is exceptionally strong (about 98–99% in 2024–2025), which is a key strength. However, profitability remains deeply negative: 2025 net loss was -$724.9M (about -200% net margin), and EBIT/EBITDA are materially negative, indicating the cost structure is still far from breakeven despite the revenue ramp.

Balance Sheet

The balance sheet is pressured by persistently negative stockholders’ equity (about -$2.08B in 2025), which materially weakens financial flexibility and increases refinancing risk. Total debt improved dramatically in 2025 (down to ~$10.0M from ~$1.73B in 2024), a meaningful positive change, but negative equity still signals an accumulated deficit and limits cushion against ongoing losses. Total assets are relatively stable around ~$0.9B in 2024–2025.

Cash Flow

Cash burn remains heavy and consistent with an R&D-intensive biotech profile: operating cash flow was -$445.9M in 2025 and free cash flow was -$447.0M, with free cash flow worsening versus 2024 (free cash flow growth -24.9% in 2025). A modest positive is that free cash flow and net income move closely together (free cash flow to net income ~1.0 across years), suggesting losses are largely cash-funded rather than driven by large non-cash addbacks. Still, the magnitude of ongoing outflows implies continued dependence on external funding or further balance-sheet actions.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	502.08M	221.90M	9.30M	77.65M	69.72M
Gross Profit	473.81M	218.02M	6.86M	74.21M	66.60M
EBITDA	-672.88M	-436.83M	-565.47M	-397.44M	-533.83M
Net Income	-729.31M	-535.76M	-643.20M	-481.18M	-562.54M
Balance Sheet
Total Assets	936.02M	919.34M	546.38M	623.04M	1.01B
Cash, Cash Equivalents and Short-Term Investments	587.48M	681.10M	434.88M	471.92M	836.66M
Total Debt	2.73B	1.73B	1.74B	1.72B	1.73B
Total Liabilities	3.01B	2.38B	1.89B	1.87B	1.88B
Stockholders Equity	-2.08B	-1.47B	-1.35B	-1.25B	-870.41M
Cash Flow
Free Cash Flow	-447.01M	-521.66M	-529.03M	-425.81M	-546.18M
Operating Cash Flow	-445.91M	-520.73M	-527.72M	-419.49M	-497.93M
Investing Cash Flow	-24.49M	60.78M	54.03M	453.15M	-200.83M
Financing Cash Flow	359.29M	748.46M	451.54M	-13.13M	736.45M

BridgeBio Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 65.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Negative. The current price of 65.36 is below the 20-day moving average (MA) of 69.55, below the 50-day MA of 73.65, and above the 200-day MA of 58.14, indicating a neutral trend. The MACD of -2.47 indicates Positive momentum. The RSI at 37.94 is Neutral, neither overbought nor oversold. The STOCH value of 37.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BBIO.

BridgeBio Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	76 Outperform	$10.72B	12.10	35.53%	―	9.93%	54.33%
BMRN	74 Outperform	$11.65B	32.67	5.94%	―	12.31%	60.21%
MRNA	58 Neutral	$21.26B	-4.07	-28.87%	―	-56.00%	-38.95%
MDGL	55 Neutral	$10.08B	―	-42.49%	―	864.21%	48.12%
IONS	53 Neutral	$12.42B	-33.22	-70.72%	―	20.39%	34.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BBIO	50 Neutral	$12.83B	―	―	―	62.46%	-73.59%

BridgeBio Pharma Corporate Events

BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results

On February 12, 2026, BridgeBio reported positive topline results from its global Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia, showing a highly significant improvement in annualized height velocity over placebo at Week 52 and the highest absolute growth rates yet seen in a randomized achondroplasia study. The trial also met a key secondary endpoint on height Z‑score and, in children under eight, delivered the first statistically significant improvement in body proportionality versus placebo for any therapy in this condition.

Infigratinib was well tolerated, with no drug‑related discontinuations or serious adverse events and only mild, transient hyperphosphatemia, and no safety signals typically associated with FGFR1/2 inhibition or CNP analogues. On the back of these data, BridgeBio plans regulatory submissions for achondroplasia in the second half of 2026 and is accelerating Phase 3 development of infigratinib in hypochondroplasia, moves that could broaden treatment options and reinforce its position in the emerging market for targeted, oral therapies for skeletal dysplasias.

The most recent analyst rating on (BBIO) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.

BridgeBio Pharma Issues New Convertible Notes and Repurchases Stock

On January 21, 2026, BridgeBio Pharma, Inc. issued $632.5 million of 0.75% Convertible Senior Notes due 2033 in a Rule 144A private placement to qualified institutional buyers, including $82.5 million issued pursuant to the initial purchasers’ option, generating approximately $619.3 million in net proceeds. The senior unsecured notes, which carry semiannual interest and are convertible into cash, common stock or a combination at BridgeBio’s election, are intended primarily to refinance or prefund a portion of the company’s 2.50% Convertible Senior Notes due 2027 and to support general corporate purposes, while maintaining pari passu ranking with BridgeBio’s existing convertible notes and extending the company’s debt maturity profile. Concurrent with the note offering’s closing on January 21, 2026, BridgeBio used about $82.5 million of cash on hand to repurchase 1,081,825 shares of its common stock in privately negotiated transactions at $76.26 per share, a move that formed part of its broader long-term debt management strategy aimed at strengthening the balance sheet, lowering interest expense, reducing dilution, and significantly extending debt maturities, with potential effects on the trading dynamics of both its stock and the new notes.

The most recent analyst rating on (BBIO) stock is a Buy with a $88.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.

BridgeBio Showcases Attruby Growth and Pipeline Progress

On January 12, 2026, BridgeBio Pharma used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to highlight strong early commercial traction for Attruby, its ATTR-CM therapy, reporting preliminary unaudited 2025 net product revenue of $362.4 million, supported by 6,629 unique patient prescriptions from 1,632 prescribers, and to announce a new TTR amyloid-depleting antibody program expected to progress to the clinic between 2027 and 2028. The company also reported pivotal data and regulatory momentum across its late-stage pipeline, including a positive interim Phase 3 FORTIFY readout in LGMD2I/R9 that prompted FDA guidance to pursue a traditional full approval pathway and an NDA filing planned for the first half of 2026, an NDA timeline in the same period for encaleret in ADH1 amid rapid growth in diagnosed patients, a planned Phase 3 trial of encaleret in chronic hypoparathyroidism starting in summer 2026, and advancing registrational studies of infigratinib in pediatric achondroplasia and hypochondroplasia, all underpinned by approximately $587.5 million in cash and marketable securities at year-end 2025 to support continued Attruby growth and potential global launches of up to three additional medicines.

The most recent analyst rating on (BBIO) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.